Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below

      DUODOPA (levodopa/carbidopa intestinal gel)

      triple all 1
      triple all 4

      DUODOPA
      (levodopa/carbidopa intestinal gel)

      triple all 1
      triple all 4

      PRODUODOPA (foslevodopa/foscarbidopa solution for infusion)

      triple all 1
      triple all 2
      triple all 3

      PRODUODOPA
      (foslevodopa/foscarbidopa solution for infusion)

      triple all 1
      triple all 2
      triple all 3
      tftt banner
      mobile varient

      A look at Complex/Advanced Parkinson's disease

      DUODOPA (levodopa/carbidopa intestinal gel) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1

      PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.2,3

      Levodopa may activate malignant melanoma, so PRODUODOPA and DUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.1-3

      Some patients may not be suitable for DUODOPA or PRODUODOPA. You are strongly advised to read the Prescribing Information (PI) and Summary of Product Characteristics (SmPC), accessible via the links above, to evaluate patient suitability.

      Consider assessing earlier?

      Peer-reviewed opinions support earlier introduction of non-oral therapies in patients with Complex/Advanced Parkinson’s disease4

      When left too late, non-oral therapies may no longer be an appropriate treatment option for patients with PD4

      When initiation of non-oral therapies is left too late, progressive neurodegeneration in PD can mean patients’ capacity to respond to these treatments may be significantly reduced.4,5

      In patients with PD, consider non-oral therapies before severe motor symptoms and loss of functioning worsen.6

      Based on a peer-reviewed opinion article that aimed to support the social and economic benefits of optimised treatment for patients with PD

      Early introduction of non-oral therapies may allow patients with PD to have better control of motor symptoms and an impact on quality of life, which may allow patients to live at home or stay at work for longer7

      View Study Information

      Hospital Episode Statistics (HES) data (2013–2018)8*

      Patients with Complex/Advanced PD treated with non-oral therapies

      compared to

      Patients with Complex/Advanced PD without dementia and not receiving non-oral therapies

      3.6

      fewer mean emergency admissions over 5 years†

      45.9

      %

      fewer patients with emergency admissions

      53.2

      fewer mean 5-year bed days†

      6.7

      %

      fewer patients with record of hip fracture‡

      Patients with Complex/Advanced PD treated with non-oral therapies

      compared to

      Patients with Complex/Advanced PD without dementia and not receiving non-oral therapies

      3.6

      fewer mean emergency admissions over 5 years†

      45.9%

      fewer patients with emergency admissions

      53.2

      fewer mean 5-year bed days†

      6.7%

      fewer patients with record of hip fracture‡

      Patients with Complex/Advanced PD treated with non-oral therapies had fewer emergency hospital admissions and hip fractures compared to those on other treatment8*†‡

      *Hospital Episode Statistics (HES) is a database of administrative healthcare data maintained by NHS digital. This applies to England only. †Means are total admissions over 5 years divided by no. of patients. ‡Any diagnosis of fracture of femur (ICD-10 Code S72).8

      HES data for Complex/Advanced PD patients8

      Parkinson’s UK estimated the prevalence of PD in England at 114,560 in 2015*†8

      Measure
      All units are N unless specified      		 All advanced
      PD patients‡      		 Advanced PD patients‡ without dementia and no advanced treatment Advanced treatment patients§
      Patients 13,310 7,106 2,499
      Males (%) 62.3 59.2 67.7
      Mean age (years) 74.2 77.2 61.9
      Mean 5-year admissions** 7.4 7.2 6.7
      Mean 5-year emergency admissions** 4.9 5.3 1.7
      Patients with emergency admission (%) 90.2 98.4 52.5
      Mean 5-year bed days** 72.3 75.7 22.5
      Patients with overnight stay (%) 97.3 98.7 89.3
      Patients with any record of dementia (%)†† 29.8 0.0 10.3
      Patients with any record of hip fracture (%)‡‡ 8.7 9.3 2.6

      *PD patients: patients with any diagnosis of PD, primary or secondary (ICD-10 code G20, PD). †Estimated value using age and gender-specific prevalence rates from the Clinical Practice Research Datalink (CPRD) and extrapolated to the population of England in mid-2015 to estimate the number of people living with Parkinson’s. The study population consisted of patients aged 20 or over with a record for Parkinson’s in their clinical or referral file during the period 1 January 1988 to 31 December 2015. Patients with <6 months of up-to-standard follow-up in the CPRD were also excluded. ‡Advanced PD patients: patients with a primary diagnosis of PD AND any diagnosis of abnormalities of gait and mobility (ICD-10 code R26, abnormalities of gait and mobility) OR any diagnosis of dyskinesia (ICD-10 codes G248/249, G248 (other dystonia) and G249 (dystonia unspecified) record dyskinesia where it is not specified in G240–247). §Advanced treatment patients: patients with a record of deep brain stimulation, apomorphine or Duodopa (levodopa/carbidopa intestinal gel). Age at first admission with any Parkinson’s disease diagnosis. **Means are total admissions over 5 years divided by number of patients. ††Any diagnosis of either Dementia in Parkinson’s disease (ICD-10 Code F023) or Hallucinations (R44) or Persistent delusional disorders (F22). ‡‡Any diagnosis of Fracture of Femur (ICD-10 Code S72).

      Discover more about the ‘5 or 2 or 1’ criteria

      Learn more

      Stay connected

      Keep up to date with future resources, support, and guidance to help you manage your patients with PD by filling out your details below and joining the mailing list.

      Please only fill out your details if you are a UK registered healthcare professional.

      Please enter First name
      Please enter Last name
      E-mail address is not valid
      Please enter Hospital name
      I consent to receive AbbVie Ltd communications


      Please refer to the AbbVie privacy notice for more information on how AbbVie processes your personal data and your data privacy rights.

      *Denotes mandatory field

      Incorrect. Please try again.

      1. DUODOPA (levodopa/carbidopa intestinal gel) SmPC.

      2. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) GB SmPC.

      3. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) NI SmPC.

      4. Mills J, Martin A. Br J Neurosci Nurs. 2015; 11(2): 92–7.

      5. Thanvi BR, Lo TCN. Postgrad Med J. 2004; 80(946): 452–8.

      6. Worth PF. Pract Neurol 2013; 13: 140–52.

      7. Lökk J, et al. Eur Neurol Rev. 2012; 7(2): 113–7.

      8. AbbVie Ltd. Data on File. REF-37728.

      DUODOPA PRESCRIBING INFORMATION
      PRODUODOPA PRESCRIBING INFORMATION

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-PRODD-230066. Date of preparation: December 2023

      Lökk J, et al. 20127

      Study type: Peer-reviewed opinion article.

      Aim: To support the social and economic benefits of optimised treatment for patients with Parkinson’s disease.

      Methods: Commentary on the economic burden of Parkinson’s disease (PD) citing 10 publications concerning health economic data and modelling, including an economic simulation study that compared the costs of standard of care vs. duodopa®(levodopa/carbidopa intestinal gel).

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.